What question did this study set out to answer?

This research aims to explore the effectiveness of TLR-3-activated umbilical cord blood-derived mesenchymal stromal cells (CB-MSCs) for treating synovial sepsis.

April 21, 2026

Toll-like receptor 3–activated allogeneic umbilical cord blood–derived mesenchymal stromal cells as an adjunct for the treatment of synovial sepsis in 3 horses

Key Points

This research aims to explore the effectiveness of TLR-3-activated umbilical cord blood-derived mesenchymal stromal cells (CB-MSCs) for treating synovial sepsis.
Utilized a case series approach.
Administered TLR-3-activated CB-MSCs as adjunctive therapy.
Included horses with chronic or antimicrobial-resistant infections.
Demonstrated positive outcomes in the management of synovial sepsis.
Improved healing in horses with chronic infections.
Highlighted potential for TLR-3 activation to enhance therapeutic effectiveness.

Abstract

Because of the increasing emergence of AMR infections in both veterinary species and humans, the advancement of alternative and synergistic therapeutics is imperative. This case series highlights the use of TLR-3-activated CB-MSCs as an adjunctive treatment in cases of synovial sepsis involving chronic or AMR infections.

Bookmark

Toll-like receptor 3–activated allogeneic umbilical cord blood–derived mesenchymal stromal cells as an adjunct for the treatment of synovial sepsis in 3 horses

Key Points

Abstract

Cite This Study